Atossa Genetics (ATOS) Starts Presentation at LD Micro Main Event
Atossa Genetics (NASDAQ: ATOS) is a clinical-stage pharmaceutical company focusing on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. For more information, visit the company's website at www.atossagenetics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array…







